Ghias ul Hassan and Bilal Nasir and Israr ul Haque and ShafiqAwan and Ghias Un NabiTayyab and S. Hassan Akhtar Bokhari and Khawar Saeed and Qazi Masroor
Efficacy of Biosimilar Pegylated Interferon Alpha 40 KD (Peg INF) in Chronic Hepatitis C Infection
945 - 948
2013
7
12
International Journal of Medical and Health Sciences
https://publications.waset.org/pdf/9996886
https://publications.waset.org/vol/84
World Academy of Science, Engineering and Technology
Introduction Pegylated Interferon and Ribavirin combination is standard of care in the management of chronic HCV infected patients. Efficacy of the therapy is judged by the ability to achieve biochemical and virological response as judged by RVR, EVR, ETR and SVR.Objective To evaluate the efficacy of newly marketed biosimilar Pegylated Interferon Alpha 40KD (Peg INF) in chronic HCV patients. Materials and methods This was observational, prospective multicentre study to evaluate the ability of biosimilar pegylated interferon alfa 2a (40KD) along with Ribavirin (weight based) to achieve SVR. The enrolled patients were separated into Naïve (A), Relapsers (B) and Non Responders(C) based on the previous history of interferon exposure and its response. The RGT was followed on ALT and RVR, EVR, ETR and SVR.ResultsAs per protocol analysis estimated SVR for three groups is 86.6 for naïve, 89.4 for relapsers and 52.4 for nonresponders to standard interferon. Conclusion It is concluded that Biosimilar pegylated interferon alfa2a (40kD) along with Ribavirin has good antiviral efficacy in Naïve, Relapsers and Nonresponders to standard IFN of chronic HCV infected patients requiring treatment.
Open Science Index 84, 2013